UK Medical Cannabis Market Booms While Vulnerable Patients Face Supply Crisis
While the private medical cannabis market expands rapidly across Britain, vulnerable patients dependent on specialized oils face severe access barriers and impending supply shortages.
At a glance
- Medical cannabis was legalized in the UK in 2018, but NHS prescriptions for unlicensed products like Bedrolite remain extremely rare.
- Patients rely heavily on the private market, where treatments can cost up to 4,000 pounds a month.
- Bedrocan, the Dutch producer of the anti-epileptic cannabis oil Bedrolite, has declared bankruptcy.
- Target Healthcare has secured a temporary six-month stockpile of Bedrolite for UK families, but long-term availability remains uncertain.
When medicinal cannabis was legalized in the UK in 2018 following intense campaigning from families of sick children, patients hoped life-saving treatments would become accessible. Yet, years later, many vulnerable individuals still cannot secure NHS prescriptions, forcing them to rely on an expensive private healthcare market.
That fragile private route is now under severe threat following the bankruptcy of Bedrocan, a Dutch company that produces Bedrolite, a specialized cannabis oil essential for controlling severe epilepsy in patients like artist Louis Petit. Although a UK manufacturer has stepped in with a temporary six-month stockpile, families and campaigners are warning that systemic neglect by successive governments has left patients stranded.
Healthcare Access
Commercial cannabis companies flourish by offering wellness treatments, vape pens, and home delivery for conditions like anxiety and chronic pain, while patients with complex medical needs face a wall of refusal from public healthcare.
Data cited up to 2025 shows that fewer than five prescriptions for unlicensed cannabis-based products like Bedrolite were distributed across the entire NHS. Consequently, patients have had to finance their own care through private clinics at costs reaching up to 4,000 pounds monthly.
Supplier Bankruptcy
The financial collapse of Bedrocan has triggered panic among families relying on Bedrolite, which cannot be substituted with generic cannabis products due to its specific formulation for drug-resistant epilepsy.
While UK drug manufacturer Target Healthcare recently informed families it has secured a six-month supply of the medication to offer temporary relief, the long-term availability of the drug beyond that window remains entirely unclear.
Analysis
The coexistence of a thriving private cannabis sector and an inaccessible public healthcare pathway highlights a deep structural failure in how the UK manages medical cannabis. While commercial suppliers profit from wellness trends, vulnerable patients remain entirely dependent on a volatile private market that leaves them exposed to international supplier bankruptcies and prohibitive costs.
What to watch: Government intervention to secure long-term supplies of Bedrolite and address barriers to NHS medical cannabis prescriptions.
Reporting from: The Guardian. Spotted an error? Tell us.
- Medical Cannabis
- NHS
- Epilepsy
- Healthcare Policy
- Pharmaceutical Industry
- United Kingdom
- Politics